Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 29:00185787241301348.
doi: 10.1177/00185787241301348. Online ahead of print.

A Retrospective Study on the Continuation of Buprenorphine in the Perioperative Setting

Morgan Lynn Dermody  1 , Sandra Lemon  2 , Lisa Kingdon  2 , Laura Ruekert  2
Affiliations

A Retrospective Study on the Continuation of Buprenorphine in the Perioperative Setting

Morgan Lynn Dermody et al. Hosp Pharm. .

Abstract

Background and Aims: The purpose of this study is to review the 2020 Substance Abuse and Mental Health Services Administration Guideline for Opioid Use Disorder recommendations to continue buprenorphine perioperatively by evaluating the total morphine milligram equivalents (MME) requirements in the first 24 hours postoperatively of patients who continued their buprenorphine therapy to those who discontinued their buprenorphine therapy perioperatively. Methods: This IRB approved study is a multicenter retrospective chart review of 80 surgical inpatients on buprenorphine prior to admission at participating sites from January 2015 to October 2022. The primary outcome is MME administered 24 hours postoperatively in patients who continued buprenorphine perioperatively versus those who discontinued buprenorphine perioperatively. Secondary efficacy outcomes included MME administered 48 and 72 hours postoperatively and daily average pain scores. Safety outcomes included rate of respiratory depression and mortality. Findings: Patients who continued buprenorphine perioperatively required significantly less MME in the first 24 hours postoperatively compared to those who discontinued buprenorphine perioperatively (median [IQR]; 23.25 [6-74.35] vs 93.38 [49.8-156.26]; P < .001). Secondary outcomes of MME administered at 48 hours (10.4 [0-40.5] vs 66.15 [27.94-143.5], P < .001) and 72 hours (0 [0-31.13] vs 66 [22.5-144], P < .001) postoperatively were also significantly less in those whose buprenorphine was continued versus those whose buprenorphine was discontinued perioperatively. Patients whose buprenorphine was continued perioperatively experienced significantly lower average pain scores at 48 (median [IQR]; 4.74 [2.9-7.08] vs 6 [4.93-7.4], P = .028) and 72 hours (3.78 [1.78-5.85] vs 5.75 [4.15-7.45], P = .002) postoperatively. Conclusion: Continuation of buprenorphine in the perioperative setting results in significantly lower utilization of MME in patients whose buprenorphine is continued compared to those whose buprenorphine is discontinued perioperatively.

Keywords: addiction; analgesics; education; medication safety; pain management; pharmacists; substance abuse.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
CONSORT diagram.
Figure 2.
Figure 2.
Average pain scores at 24, 48, and 72 hours postoperatively. *Denotes statistical significance.
See this image and copyright information in PMC

References

    1. Kohan L, Potru S, Barreveld AM, et al.. Buprenorphine management in the perioperative period: educational review and recommendations from a multisociety expert panel. Reg Anesth Pain Med. 2021;46(10):840-859. doi:10.1136/rapm-2021-103007 - DOI - PubMed
    1. Mehta D, Thomas V, Johnson J, Scott B, Cortina S, Berger L. Continuation of buprenorphine to facilitate postoperative pain management for patients on buprenorphine opioid agonist therapy. Pain Physician. 2020;23(2):E163-E174. Accessed July 26, 2022. https://www.painphysicianjournal.com/linkout?issn=&vol=23&page=E163 - PubMed
    1. Warner NS, Warner MA, Cunningham JL, et al.. A practical approach for the management of the mixed opioid agonist-antagonist buprenorphine during acute pain and surgery. Mayo Clin Proc. 2020;95(6):1253-1267. doi:10.1016/j.mayocp.2019.10.007 - DOI - PubMed
    1. Quaye AN, Zhang Y. Perioperative management of buprenorphine: solving the conundrum. Pain Med. 2019;20(7):1395-1408. doi:10.1093/pm/pny217 - DOI - PMC - PubMed
    1. Attaar A, Curran M, Meyenburg L, Bottner R, Johnston C, Roberts Mason K. Perioperative pain management and outcomes in patients who -discontinued or continued pre-existing buprenorphine therapy. J Opioid Manag. 2021;17(7):33-41. doi:10.5055/jom.2021.0640 - DOI - PubMed

LinkOut - more resources